DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 202860
» See Plans and Pricing
NDA 202860 describes GENOSYL, which is a drug marketed by Vero Biotech and is included in one NDA. There are six patents protecting this drug. Additional details are available on the GENOSYL profile page.
The generic ingredient in GENOSYL is nitric oxide. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nitric oxide profile page.
The generic ingredient in GENOSYL is nitric oxide. There are six drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nitric oxide profile page.
Summary for 202860
| Tradename: | GENOSYL |
| Applicant: | Vero Biotech |
| Ingredient: | nitric oxide |
| Patents: | 6 |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 202860
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | GAS;INHALATION | Strength | 800PPM | ||||
| Approval Date: | Dec 20, 2019 | TE: | RLD: | Yes | |||||
| Patent: | Start Trial | Patent Expiration: | Feb 12, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | Start Trial | Patent Expiration: | Oct 20, 2035 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | Start Trial | Patent Expiration: | Feb 23, 2022 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
